MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company developing breakthrough therapeutics for neurologic and neuropsychiatric disorders, today announced the enrollment of ...
Non-Invasive Ultrasound Treatment Shows Promise for Neuropathic Pain Relief, Feinstein Institutes Research Finds
Neuropathic pain affects up to 10 percent of the global population and can be challenging to manage effectively with existing ...
Managed Healthcare Executive6d
Nonopioid Pain Drug Journavx Gaining Traction With High Potential
According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ...
Morningstar3d
Non-Invasive Ultrasound Treatment Shows Promise for Neuropathic Pain Relief, Feinstein Institutes Research Finds
Neuropathic pain affects up to 10 percent of the global population and can be challenging to manage effectively with existing medications. As a possible alternative treatment option, scientists at ...